What we’re doing differently at JP Morgan this yearnews2024-01-04T12:00:54+00:00January 4th, 2024|Endpoints News|
Kymera doubles down on protein degraders for immunology, chasing Dupixent and Sotyktunews2024-01-04T12:00:14+00:00January 4th, 2024|Endpoints News|
Ex-Turning Point leaders license first oncology assets for new startup Avenzonews2024-01-04T12:00:13+00:00January 4th, 2024|Endpoints News|
Novo’s broad Flagship partnership starts with obesity at Omega and MASH at Cellaritynews2024-01-04T11:00:49+00:00January 4th, 2024|Endpoints News|
Full-Life Technologies raises $63.3M to start clinical trial, build manufacturing facility for radiotherapiesnews2024-01-04T00:00:02+00:00January 4th, 2024|Endpoints News|
Every FDA drug approval from 2023: Full list of approved new drugsnews2024-01-03T20:30:46+00:00January 3rd, 2024|Endpoints News|
Dr. Reddy’s, Torrent Pharma and Laurus Synthesis all land Form 483 letters following FDA inspectionsnews2024-01-03T20:06:04+00:00January 3rd, 2024|Endpoints News|
No FDA drug or biologic adcomms scheduled for 2024 so far, calendar showsnews2024-01-03T20:00:28+00:00January 3rd, 2024|Endpoints News|
Bausch + Lomb puts new spin on annual glaucoma campaign with a focus on ‘Faces’news2024-01-03T19:28:19+00:00January 3rd, 2024|Endpoints News|
GSK shrinks Scynexis deal after delay in commercialization of antifungal drugnews2024-01-03T19:04:41+00:00January 3rd, 2024|Endpoints News|
